SLC22A12 and hyperuricemia: Animal experiments have shown that TZD drugs indirectly regulate the expression of UAT and URAT1 mRNA by improving IR and reducing blood insulin levels, thereby reducing hyperuricemia caused by hyperinsulinemia.